Related Experiment Video

Updated: Aug 19, 2026

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Inhibiting Ras signaling in the therapy of breast cancer

Tianhong Li1, Joseph A Sparano

  • 1Albert Einstein Cancer Center, Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA.

Clinical Breast Cancer
|March 15, 2003
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) show promise in treating breast cancer by inhibiting Ras protein prenylation. These inhibitors demonstrate antiproliferative effects in both mutated and wild-type Ras cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras proteins are key regulators of cellular processes, and their aberrant activation through mutations drives cancer development.
  • Prenylation of Ras proteins by farnesyltransferase is essential for their membrane localization and function.
  • Farnesyltransferase inhibitors (FTIs) were developed to target Ras-driven cancers but show potential in other cancer types.

Purpose of the Study:

  • To investigate the antiproliferative and antitumor effects of FTIs in breast cancer.
  • To explore the potential of FTIs in combination with other cancer therapies.

Main Methods:

  • Preclinical studies using breast cancer cell lines (both Ras-mutated and wild-type).
  • Evaluation of FTI efficacy in a Phase II clinical trial for metastatic breast cancer.
  • Assessment of FTI synergy with cytotoxic agents and hormonal therapy.

Main Results:

  • FTIs exhibit antiproliferative and antitumor effects in preclinical breast cancer models.
  • One orally administered FTI demonstrated significant antitumor activity in metastatic breast cancer patients.
  • Preclinical data suggest FTIs may enhance the efficacy of chemotherapy and hormonal treatments.

Conclusions:

  • FTIs represent a promising therapeutic strategy for breast cancer, including those with wild-type Ras.
  • Further clinical trials are warranted to establish the role of FTIs in advanced breast cancer management.
  • FTIs may offer a synergistic approach when combined with existing breast cancer therapies.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...